Good Pharmacovigilance Practices: GVP Modules Explained for MAHs and PV Teams

Understanding good pharmacovigilance practices helps marketing authorisation holders (MAHs) build compliant safety systems. Reliable pharmacovigilance services can further support the efficient implementation of regulatory expectations and day-to-day pharmacovigilance activities.

What Are Good Pharmacovigilance Practices (GVP)?

EMA Good Pharmacovigilance Practices are a collection of guidance documents that define how medicines should be monitored throughout their lifecycle after approval. Developed by the European Medicines Agency (EMA), they establish a harmonised framework for managing safety responsibilities across the European Union.

These guidelines apply to marketing authorisation holders, service providers, and organisations involved in pharmacovigilance. They describe how companies should organise their PV system, maintain quality standards, document activities, and fulfil pharmacovigilance requirements expected by regulators.

Beyond defining responsibilities, GVP promotes consistent approaches to monitoring product safety, evaluating emerging evidence, and protecting patients through effective oversight. Combined with pharmacovigilance literature monitoring, the framework supports the timely identification of information relevant to medicinal safety throughout a product’s lifecycle.

Overview of the Valid GVP Modules

The GVP (Good Pharmacovigilance Practices) framework currently includes 12 active process-related modules, numbered I–X and XV–XVI. Together, these documents describe the core activities required to maintain an effective pharmacovigilance system throughout the product lifecycle.

Module I — Pharmacovigilance Systems and Quality Systems

Module I explains how organisations should establish and maintain an effective pharmacovigilance system. It describes governance structures, quality management principles, documented procedures, staff responsibilities, and oversight mechanisms. The module also introduces the role of the qualified person responsible for supervising the overall system and ensuring that safety responsibilities are consistently carried out.

Module II — Pharmacovigilance System Master File (PSMF)

Module II focuses on the Pharmacovigilance System Master File, which documents how a company organises and operates its pharmacovigilance activities. The PSMF provides inspectors with a comprehensive overview of organisational structure, responsibilities, procedures, databases, vendors, and quality controls. Maintaining an accurate, up-to-date master file is essential to demonstrating operational transparency.

Module III — Pharmacovigilance Inspections

This module explains how competent authorities inspect pharmacovigilance systems to verify regulatory compliance. It outlines inspection planning, preparation, execution, reporting, and follow-up activities. Companies are expected to maintain complete documentation, demonstrate process effectiveness, and implement corrective and preventive actions whenever inspection findings are identified.

Module IV — Pharmacovigilance Audits

Module IV describes how internal audits independently assess whether pharmacovigilance systems function as intended. It covers audit planning, risk-based scheduling, reporting, and follow-up activities. Regular audits help organisations identify weaknesses before inspections while promoting continuous quality improvement and better organisational oversight.

Module V — Risk Management Systems

Module V explains how companies develop, implement, and maintain risk management plans throughout a product’s lifecycle. It describes methods for identifying known and potential risks, evaluating the risk-benefit balance, and defining appropriate risk minimisation measures. The module also explains how these activities evolve as new evidence becomes available after authorisation.

Module VI — Collection and Reporting of Suspected Adverse Reactions

Module VI provides detailed guidance on collecting, assessing, documenting, and reporting suspected adverse drug reactions from multiple sources. These include spontaneous reports, scientific publications, and information received through digital channels. Accurate case processing supports the timely submission of valid safety reports while ensuring data quality and regulatory consistency.

Module VII — Periodic Safety Update Reports

Module VII describes the preparation and submission of Periodic Safety Update Reports (PSURs). These reports provide a structured assessment of accumulated safety data collected throughout a product’s lifecycle. Rather than listing individual cases, PSURs evaluate whether the overall benefit-risk profile has changed and determine whether further regulatory action or product updates are required.

Module VIII — Post-Authorisation Safety Studies

Module VIII provides guidance on designing and conducting post-authorisation safety studies when additional evidence is needed after marketing authorisation. These studies help address specific research questions, evaluate product use in routine clinical practice, and generate information that may not have been available during clinical trials.

Module IX — Signal Management

Module IX explains how organisations detect, validate, prioritise, assess and recommend actions for emerging safety signals. Information may originate from spontaneous reports, scientific publications, observational studies, or other surveillance sources. Effective signal management enables companies to identify potential drug safety issues early and support informed regulatory decision-making.

Module X — Additional Monitoring

Module X describes the additional monitoring scheme applied to selected medicinal products that require enhanced observation after authorisation. Products under additional monitoring encourage increased reporting of suspected adverse reactions, allowing regulators and marketing authorisation holders to gather further evidence about their safety profile in real-world use.

Module XV — Safety Communication

Module XV focuses on communicating important safety information to stakeholders in a timely, transparent and understandable manner. It outlines principles for preparing Direct Healthcare Professional Communications (DHPCs), public announcements, educational materials and other communications that help minimise risk while maintaining confidence in medicines.

Module XVI — Risk Minimisation Measures

Module XVI explains how additional risk minimisation measures should be planned, implemented and evaluated when routine activities alone are insufficient. Educational programmes, controlled distribution systems and patient materials may all contribute to reducing identified risks while supporting the safe use of medicines.

Which GVP Modules Matter Most for MAHs and PV Teams?

Although every GVP module contributes to an effective pharmacovigilance framework, the EMA Good Pharmacovigilance Practices (GVP) overview emphasizes that three modules are especially relevant for the daily work of marketing authorisation holders because they directly influence operational workflows and regulatory submissions.

Module VI and Adverse Reaction Reporting

For most PV teams, Module VI is one of the most operationally intensive documents. It establishes expectations for collecting reports from spontaneous sources, scientific publications, and digital channels; assessing report validity; documenting cases; and submitting them in accordance with applicable regulatory requirements. Since literature remains an important source of potential ICSRs, consistent review processes are essential for maintaining high-quality case processing.

Module VII and Periodic Safety Evaluation

Module VII supports periodic evaluation of cumulative pharmacovigilance data rather than isolated cases. Information gathered from multiple sources contributes to a comprehensive understanding of product performance over time. This systematic approach enables organisations to identify meaningful trends and prepare robust benefit-risk assessments for regulatory review.

Module IX and Signal Management

Signal management depends on continuous monitoring of multiple information sources and on effective collaboration among functional teams. Scientific publications, spontaneous reporting systems and observational research all contribute valuable evidence for drug evaluation. Efficient prioritisation allows experts to focus on information that may require further clinical assessment or regulatory action.

Medical Literature Monitoring Under Good Pharmacovigilance Practices

Systematic medical literature monitoring plays an essential role in supporting several GVP modules, particularly those related to case collection, signal detection and ongoing safety evaluation.

Why Literature Monitoring Matters in Pharmacovigilance

Scientific literature remains one of the most valuable external sources of safety evidence. Published articles may describe previously unreported adverse events, emerging safety concerns, new patient populations or changes in clinical practice. Continuous monitoring helps organisations identify information relevant to patient safety, supports informed regulatory decisions, and contributes to broader post-marketing surveillance activities.

Literature monitoring also supports collaboration between healthcare professionals, researchers and pharmaceutical companies, ensuring that important findings published in scientific journals become part of routine pharmacovigilance practice.

From Literature Screening to Potential ICSR Identification

An effective literature monitoring workflow begins with systematic searches across relevant databases and local journals. Publications are retrieved using predefined search strategies and screened to determine whether they contain information relevant to pharmacovigilance.

Potentially relevant articles undergo scientific review to identify reportable cases, assess data completeness and determine whether they meet applicable reporting criteria. Every decision should remain fully traceable, from article retrieval through review outcomes and documentation, creating a complete audit trail.

When publications contain potential reportable cases or other clinically important findings, they are escalated to PV specialists for detailed assessment. This structured approach supports consistent pharmacovigilance processes, reduces manual workload and improves transparency throughout the review lifecycle.

Common GVP Compliance Challenges for PV Teams

Meeting GVP expectations becomes increasingly challenging as scientific publications continue to grow in both volume and complexity. Even experienced teams may struggle to review every relevant article while maintaining consistency and complete documentation.

Common challenges include:

• rapidly growing literature volumes;
• extensive manual screening workload;
• inconsistent review approaches across reviewers;
• missed relevant publications;
• documentation and audit trail expectations;
• changing regulatory guidance and inspection readiness.

These challenges can affect multiple major pharmacovigilance processes, particularly where large numbers of publications require timely review. Maintaining documented procedures, demonstrating traceability and coordinating work across a compliance management team require significant resources.

In addition, organisations operating across multiple EU Member States must adapt their workflows to different operational environments while continuing to satisfy harmonised European expectations.

How Automation Can Support GVP-Compliant Literature Monitoring

Modern software can improve efficiency while supporting consistent review practices and documented decision-making.

Automated Search and Article Screening

Automation can assist with literature searches, duplicate removal, article classification and prioritisation. AI-assisted screening enables reviewers to focus on publications more likely to contain relevant safety information, reducing time spent on low-value articles while preserving expert oversight.

Traceability, Documentation and Human Oversight

Solutions such as DrugCard Literature Monitoring provide structured workflows for literature review, documentation and collaboration. While expert assessment remains essential, automation can support GVP-compliant pharmacovigilance activities by improving traceability, maintaining review records and facilitating consistent decision-making across teams. Importantly, technology supports human expertise – it does not replace regulatory judgement.

Frequently Asked Questions About GVP

What does GVP mean in pharmacovigilance?

GVP refers to a collection of European guidelines that describe how organisations should establish, maintain, and continuously improve pharmacovigilance systems after medicines receive marketing authorisation.

How many GVP modules are there?

The current framework contains 12 active process-related modules: I–X and XV–XVI. Historical module numbers XI-XIV are no longer active within the GVP framework.

Which GVP module covers literature monitoring?

Literature monitoring is primarily addressed in Module VI because published scientific articles may contain reportable safety cases that require assessment and regulatory reporting.

Why is literature monitoring important for MAHs?

Continuous literature review helps organisations identify relevant publications, detect emerging safety concerns, and maintain well-documented pharmacovigilance workflows that support regulatory expectations.

Can pharmacovigilance literature monitoring be automated?

Yes. Modern software can automate searching, screening, prioritisation and documentation while qualified reviewers remain responsible for scientific assessment and final regulatory decisions.